HTDS news: B: Hard to Treat Diseases, Incorporated's Motion for Partial Summ
ry Judgment is Under Advisement by Court ( PRIMEZONE
B: Hard to Treat Diseases, Incorporated's Motion for Partial Summary Judgment is
Under Advisement by Court ( PRIMEZONE )
DELRAY BEACH, Fla., Jan 26, 2005 (PRIMEZONE via COMTEX) -- Hard to Treat
Diseases, Incorporated (HTTD) (Pink Sheets:HTDS) announced today that the
Federal Court heard oral argument on the Company's Motion for Partial Summary
Judgment Against Defendants Shinn and Knight during a hearing held on January
20, 2005.
During the hearing before the Court, HTTD presented a concise overview of the
facts and legal arguments, with reference to specific exhibits, to the Court.
The Company's position has been consistent throughout this litigation.
Defendants have presented three alternative and sometimes inconsistent responses
to HTTD's claims. These claims, issues, defenses, and references to facts had
been extensively briefed and filed with the Court prior to the hearing. The
Federal Court carefully listened to the arguments and points of the Company and
Defendants Shinn and Knight and advised the parties that it will review the
Parties' briefs before issuing a ruling.
At the close of the hearing, the Court acknowledged that in many
business-related disputes it is in the best interests of the parties to seek a
negotiated resolution before trial. However, the Court noted that the parties
may seek to move towards a trial as soon as practicable.
The Federal Judge's ruling will be posted on HTTD's website at: www.htdsotc.com
and a press release issued as soon as the ruling is received.
Management's intention and goal with this litigation is to resolve the current
dispute in the most efficient and economical manner to provide the maximum
benefit to the Company and to HTTD's shareholders.
HTTD is currently involved in litigation regarding the rights to Tubercin (r).
Additional information and details regarding the litigation can be viewed at our
website at: www.htdsotc.com
Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Securities Act of 1933, as
amended. Those statements include statements regarding the intent, belief or
current expectations of the Company and its management. Such statements reflect
management's current views, are based on certain assumptions and involve risks
and uncertainties. Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not limited to,
our ability to obtain additional financing and access funds from our existing
financing arrangements that will allow us to continue our current and future
operations and whether demand for our product and testing service in domestic
and international markets will continue to expand. The Company undertakes no
obligation to publicly update these forward-looking statements to reflect events
or circumstances that occur after the date hereof or to reflect any change in
the Company's expectations with regard to these forward-looking statements or
the occurrence of unanticipated events.
SOURCE: Hard to Treat Diseases, Inc.
By Staff
CONTACT: Hard to Treat Diseases, Incorporated
Colm J. King, CEO
(561) 272-6900
www.htdsotc.com
